01:14 PM EDT, 06/28/2024 (MT Newswires) -- CG Oncology's ( CGON ) cretostimogene immunotherapy to treat bladder cancer is expected to achieve over $4 billion in non-risk adjusted sales by 2037, BofA Securities said in a note Friday.

Cretostimogene holds promising potential as a leading candidate in high-risk non-muscle bladder invasive bladder cancer, or NMIBC, in a highly competitive market. Final phase 3 data is anticipated in December 2024 and a potential market launch in early 2026, BofA said.

"Intermediate-risk NMIBC represents a higher bar for treatment to replace the standard of care," BofA said. Cretostimogene may also benefit patients with limited or no prior Bacillus Calmette-Guerin treatment, it added.

BofA Securities initiated CG Oncology's ( CGON ) coverage at buy and a price objective of $65.

Price: 31.38, Change: +1.13, Percent Change: +3.74